Maurice Mezzino - Arena Pharmaceuticals Senior Vice President - Corporate Development
ARNADelisted Stock | USD 99.99 0.00 0.00% |
President
Mr. Maurice J. Mezzino is Senior Vice President Corporationrationrate Development of the company since December 2015, and previously served as our Vice President, Corporationrationrate Development from August 2011 to December 2015. Mr. Mezzino has over 30 years of experience in the biopharmaceutical industry related to partnering, assessing new businesses, products and markets, and planning with respect to strategy and operations. Mr. Mezzino has successfully led crossfunctional teams to source, structure, negotiate and execute deal transactions on products and technologies in various stages of commercialization and in multiple therapeutic markets. Mr. Mezzino served in a consulting capacity as Acting Vice President of Business Development for BeiGene, Ltd., an immunooncology company, from January 2011 to August 2011 as Vice President, Chief Business Officer at Ceregene, Inc., a former neurodegenerative diseasefocused gene therapy company, from 2008 to 2010 in various positions at IDEC Pharmaceuticals Corporationrationration, a biopharmaceutical company and continuing at Biogen Idec Inc. after the since 2015.
Age | 60 |
Tenure | 9 years |
Phone | 858 453-7200 |
Web | www.arenapharm.com |
Arena Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (34.53) % which means that it has lost $34.53 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (70.3) %, meaning that it created substantial loss on money invested by shareholders. Arena Pharmaceuticals' management efficiency ratios could be used to measure how well Arena Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 51.31 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Arena Pharmaceuticals has a current ratio of 8.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Arena Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Arena Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arena Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arena to invest in growth at high rates of return. When we think about Arena Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Jamie Beggs | Avient Corp | 47 | |
Eric Hinkefent | AMCON Distributing | 53 | |
Daniel Monagle | Minerals Technologies | 58 | |
Vinod Purayath | Avient Corp | 45 | |
Cindi Buckwalter | Minerals Technologies | N/A | |
Michael Cipolla | Minerals Technologies | 66 | |
Thomas Meek | Minerals Technologies | 67 | |
Douglas Mayger | Minerals Technologies | 66 | |
Patrick Carpenter | Minerals Technologies | 52 | |
Courtland Pearson | Lifevantage | N/A | |
Andrew Plummer | AMCON Distributing | 50 | |
Jonathan Hastings | Minerals Technologies | 61 | |
Michelle ObornVirchow | Lifevantage | 44 | |
Matthew Garth | Minerals Technologies | 46 | |
Michael Johnson | Minerals Technologies | 55 | |
Rand Mendez | Minerals Technologies | 53 | |
Andrew Jones | Minerals Technologies | 61 | |
Brett Argirakis | Minerals Technologies | 59 | |
Rick Honey | Minerals Technologies | N/A | |
Charles Schmaderer | AMCON Distributing | 55 | |
Kenneth Wolf | Natural Alternatives Internatio | 63 |
Management Performance
Return On Equity | -70.3 | |||
Return On Asset | -34.53 |
Arena Pharmaceuticals Leadership Team
Elected by the shareholders, the Arena Pharmaceuticals' board of directors comprises two types of representatives: Arena Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arena. The board's role is to monitor Arena Pharmaceuticals' management team and ensure that shareholders' interests are well served. Arena Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arena Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Garry Neil, Director | ||
Randall Woods, Independent Director | ||
Maurice Mezzino, Senior Vice President - Corporate Development | ||
Harry Hixson, Independent Director | ||
Phillip Schneider, Independent Director | ||
Steven Spector, Executive Vice President General Counsel, Secretary | ||
Preston Klassen, Executive Vice President - Research & Development, Chief Medical Officer | ||
Jennifer Jarrett, Director | ||
Jennifer Bielasz, Vice President - Accounting, Controller, Principal Accounting Officer | ||
Robert Lisicki, Executive Vice President and Chief Commercial Officer | ||
Tina Nova, Independent Director | ||
Craig Audet, Head of Global Regulatory Affairs and Sr. VP of Operations | ||
Jayson Dallas, Director | ||
Kieran Gallahue, Director | ||
Amit Munshi, President CEO, Director | ||
William Shanahan, Senior Vice President Chief Medical Officer | ||
Donald Belcher, Independent Director | ||
Scott Bice, Independent Director | ||
Dominic Behan, Executive Vice President Chief Scientific Officer, Director | ||
Vincent Aurentz, Executive Vice President and Chief Business Officer | ||
Manmeet Soni, Director | ||
Kevin Lind, CFO, Executive Vice President | ||
Christine White, Lead Independent Director | ||
Oliver Fetzer, Director | ||
Paul Audhya, Senior Vice President - Medical Affairs |
Arena Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arena Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -70.3 | |||
Return On Asset | -34.53 | |||
Current Valuation | 5.36 B | |||
Shares Outstanding | 61.56 M | |||
Shares Owned By Insiders | 0.55 % | |||
Shares Owned By Institutions | 84.05 % | |||
Number Of Shares Shorted | 5.11 M | |||
Price To Earning | 4.53 X | |||
Price To Book | 7.65 X | |||
Revenue | 54 K |
Pair Trading with Arena Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arena Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arena Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Arena Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arena Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arena Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arena Pharmaceuticals to buy it.
The correlation of Arena Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arena Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arena Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arena Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Arena Stock
If you are still planning to invest in Arena Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Arena Pharmaceuticals' history and understand the potential risks before investing.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |